X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs NOVARTIS - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD NOVARTIS ALEMBIC LTD/
NOVARTIS
 
P/E (TTM) x 52.9 292.3 18.1% View Chart
P/BV x 2.2 32.4 6.8% View Chart
Dividend Yield % 0.5 1.4 32.7%  

Financials

 ALEMBIC LTD   NOVARTIS
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
NOVARTIS
Mar-18
ALEMBIC LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs72758 9.5%   
Low Rs34579 5.9%   
Sales per share (Unadj.) Rs4.7228.4 2.1%  
Earnings per share (Unadj.) Rs6.131.7 19.2%  
Cash flow per share (Unadj.) Rs6.232.8 19.1%  
Dividends per share (Unadj.) Rs0.2010.00 2.0%  
Dividend yield (eoy) %0.41.5 25.3%  
Book value per share (Unadj.) Rs40.7297.1 13.7%  
Shares outstanding (eoy) m267.0324.69 1,081.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.32.9 384.8%   
Avg P/E ratio x8.721.1 41.2%  
P/CF ratio (eoy) x8.520.4 41.6%  
Price / Book Value ratio x1.32.2 57.9%  
Dividend payout %3.331.5 10.4%   
Avg Mkt Cap Rs m14,13916,505 85.7%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m2071,445 14.3%   
Avg. sales/employee Rs ThNM8,441.3-  
Avg. wages/employee Rs ThNM2,163.6-  
Avg. net profit/employee Rs ThNM1,173.1-  
INCOME DATA
Net Sales Rs m1,2555,639 22.3%  
Other income Rs m3701,718 21.5%   
Total revenues Rs m1,6257,357 22.1%   
Gross profit Rs m111-63 -177.8%  
Depreciation Rs m3825 149.4%   
Interest Rs m255 3.1%   
Profit before tax Rs m4421,575 28.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m24792 3.0%   
Profit after tax Rs m1,630784 208.0%  
Gross profit margin %8.9-1.1 -798.6%  
Effective tax rate %5.450.3 10.8%   
Net profit margin %129.813.9 934.4%  
BALANCE SHEET DATA
Current assets Rs m1,8679,522 19.6%   
Current liabilities Rs m5913,296 17.9%   
Net working cap to sales %101.6110.4 92.1%  
Current ratio x3.22.9 109.3%  
Inventory Days Days9437 257.4%  
Debtors Days Days7428 258.7%  
Net fixed assets Rs m1,79146 3,893.3%   
Share capital Rs m534123 432.8%   
"Free" reserves Rs m10,3247,213 143.1%   
Net worth Rs m10,8587,336 148.0%   
Long term debt Rs m410-   
Total assets Rs m11,59111,105 104.4%  
Interest coverage x260.929.5 884.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.5 21.3%   
Return on assets %14.17.6 186.3%  
Return on equity %15.010.7 140.5%  
Return on capital %15.222.2 68.3%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1961 32.0%   
Fx outflow Rs m2643,630 7.3%   
Net fx Rs m-244-3,570 6.8%   
CASH FLOW
From Operations Rs m2361,610 14.6%  
From Investments Rs m-224687 -32.6%  
From Financial Activity Rs m-27-2,677 1.0%  
Net Cashflow Rs m-15-380 3.9%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 2.0 10.0%  
FIIs % 9.7 1.6 606.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 21.5 121.4%  
Shareholders   54,701 41,647 131.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare ALEMBIC LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Aug 14, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - UNICHEM LAB COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS